Trials / Completed
CompletedNCT03061955
Safety and Efficacy of Concurrent Administration of Influenza Vaccine in Patients Undergoing Anti-PD-1 Immunotherapy (Nivolumab, Pembrolizumab)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 28 (actual)
- Sponsor
- Wake Forest University Health Sciences · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to evaluate the safety and efficacy of concurrent administration of influenza vaccine in patients receiving anti-PD1 immunotherapy (nivolumab or pembrolizumab). This will be a prospective observational study, aiming to assess patient tolerance of treatment, adverse events (incidence, grade, need for hospitalization), incidence of influenza infections, and seroconversion rates.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | influenza vaccination | administration of influenza vaccination |
Timeline
- Start date
- 2016-10-01
- Primary completion
- 2017-03-31
- Completion
- 2019-04-26
- First posted
- 2017-02-23
- Last updated
- 2024-10-04
Source: ClinicalTrials.gov record NCT03061955. Inclusion in this directory is not an endorsement.